Department of Ophthalmology, Fukushima Medical University, 1 Hikarigaoka-cho, Fukushima, 960-1295, Japan.
Jpn J Ophthalmol. 2024 May;68(3):211-215. doi: 10.1007/s10384-024-01057-3. Epub 2024 Apr 13.
To investigate the association between the arm-to-choroidal circulation time (ACT) on indocyanine green angiography (IA) and clinical profile in patients with polypoidal choroidal vasculopathy (PCV).
Single-center retrospective study.
We included 38 eyes of 38 patients with PCV diagnosed using multimodal imaging and did not undergo previous treatment. All patients were treated with monthly aflibercept injections for 3 months and treat-and-extend regimens for the subsequent 12 months. Posterior vortex vein ACT was assessed on the first visit using Heidelberg IA. The patients were divided into two groups: ACT ≥20 s (L group; eight eyes) and ACT <20 s (S group; 30 eyes). The clinical profiles before and after treatment were analyzed to assess associations with ACT.
The mean ACT was 16.39±3.3 s (L group: 21.25±1.49 s, women:men=2:6, mean age: 77.3±6.5 years; S group: 15.10±2.17 s, women:men=7:23, mean age: 75.5±6.9 years). No significant difference was observed in the mean subfoveal choroidal thickness between the L and the S groups (176±75 μm vs. 230±79 μm, P=0.10). However, there were significant differences between the L and S groups in retinal fluid accumulation and hemorrhage recurrence (eight/eight eyes, 100% vs. 13/30 eyes, 43%, P<0.001), mean aflibercept injections (8.8±1.6 vs. 7.0±1.6, P<0.01) during the 12-month period, and the number of polypoidal lesions (1.8±0.7 vs. 1.3±0.5, P<0.05).
Patients with PCV and ACT >20 s are more likely to experience exudative change recurrence in the retina during treatment because they have more polypoidal lesions.
研究吲哚菁绿血管造影(IA)中臂-脉络膜循环时间(ACT)与息肉样脉络膜血管病变(PCV)患者临床特征之间的关系。
单中心回顾性研究。
我们纳入了 38 例(38 只眼)经多模态成像诊断为 PCV 且未接受过治疗的患者。所有患者均接受每月一次阿柏西普注射治疗 3 个月,并采用治疗-扩展方案治疗 12 个月。在首次就诊时使用海德堡 IA 评估后极涡静脉 ACT。将患者分为两组:ACT≥20 s(L 组;8 只眼)和 ACT<20 s(S 组;30 只眼)。分析治疗前后的临床特征,以评估与 ACT 的相关性。
平均 ACT 为 16.39±3.3 s(L 组:21.25±1.49 s,女性:男性=2:6,平均年龄:77.3±6.5 岁;S 组:15.10±2.17 s,女性:男性=7:23,平均年龄:75.5±6.9 岁)。L 组和 S 组的平均黄斑下脉络膜厚度无显著差异(176±75 μm vs. 230±79 μm,P=0.10)。然而,L 组和 S 组在视网膜液体积聚和出血复发(8/8 眼,100% vs. 13/30 眼,43%,P<0.001)、平均阿柏西普注射次数(8.8±1.6 vs. 7.0±1.6,P<0.01)和息肉样病变数量(1.8±0.7 vs. 1.3±0.5,P<0.05)方面存在显著差异。
ACT>20 s 的 PCV 患者在治疗过程中更有可能出现视网膜渗出性改变复发,因为他们有更多的息肉样病变。